0001181431-13-033369.txt : 20130607
0001181431-13-033369.hdr.sgml : 20130607
20130607060140
ACCESSION NUMBER: 0001181431-13-033369
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130604
FILED AS OF DATE: 20130607
DATE AS OF CHANGE: 20130607
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930797222
STATE OF INCORPORATION: OR
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 7
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-444-8424
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 7
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Martignetti Anthony
CENTRAL INDEX KEY: 0001574697
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 13898847
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 7
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
rrd382736.xml
FORM 4
X0306
4
2013-06-04
0
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001574697
Martignetti Anthony
215 FIRST STREET, SUITE 7
CAMBRIDGE
MA
02412
0
0
0
1
See Remarks
Incentive Stock Option (right to buy)
34.9200
2013-06-04
4
A
0
4901
0
A
2023-06-04
Common Stock
4901
4901
D
Non-Qualified Stock Option (right to buy
34.9200
2013-06-04
4
A
0
99
0
A
2023-06-04
Common Stock
99
99
D
This option is exercisable at the rate of 25% of the shares on the first anniversary of the date of grant and 1/48th of the total granted shares on each monthly anniversary thereafter, such that the option will be fully exercisable on the fourth anniversary of the date of grant.
On June 6, 2013, Sarepta Therapeutics, Inc., a Delaware corporation, became the successor of Sarepta Therapeutics, Inc., an Oregon corporation, pursuant to a merger. The merger had the effect of changing the state of incorporation of Sarepta Therapeutics, Inc. from Oregon to Delaware, but did not alter the proportionate interests of security holders.
Dir Finance - Chief Accounting Officer & Corporate Controller
By: David Tyronne Howton For: Anthony Martignetti
2013-06-06